Press Room


    Press Release - March 25, 2013

    Sernova Awarded Funding to Optimize its Sertolin™ Local Therapeutic Cell Anti-Rejection Technology for the Treatment of Chronic Diseases

    LONDON, ONTARIO (Marketwire -- March 25, 2013) -- Sernova Corp. ("Sernova" or the "Company") (TSX VENTURE: SVA - News) a clinical stage company today announced that it has been awarded a third non- refundable financial contribution of up to $254,000 from the National Research Council of Canada (NRC) Industrial Research Assistance Program (IRAP) for the optimization of its Sertolin(TM) technology within its Cell Pouch(TM) for the treatment of chronic diseases. This award brings the total contribution of IRAP to Sernova's Research and Development programs of over $1.0M since July 2009.

    Sernova's proprietary Sertolin(TM) technology protects therapeutic cell types, such as insulin producing islets from immune system attack locally within the Cell Pouch(TM). Sernova believes its Sertolin(TM) technology has the potential to reduce or eliminate the need for expensive lifelong daily antirejection drug cocktails that make subjects susceptible to serious infections.

    The new IRAP financial contribution is being used for a key series of studies to optimize the long-term safety and efficacy of Sertolin(TM) with insulin-producing islets in the Cell Pouch(TM). Data derived from this research will be used in a regulatory package for potential future testing in human clinical trials.

    "We are quite pleased to receive NRC-IRAP support once again," said Dr. Philip Toleikis President and CEO of Sernova. "The optimization work is in line with our company's business strategy in advancing Sernova's local immune protection technology and is an important step in bringing the possibility of safe, efficacious and cost- effective cell replacement one step closer to millions of patients with chronic debilitating diseases such as diabetes."

    "Sernova is unique in having the only proprietary human scalable technology solution for therapeutic cells (i.e. donor cells, stem cells, and xenogeneic cells) which can thrive within its Cell Pouch(TM) in a natural tissue matrix rich in blood vessels and protected by Sertolin(TM) from immune system attack," added Toleikis.

    The successful commercialization of Sernova's Cell Pouch System(TM) with local immune protection of therapeutic cells is expected to build a substantial source of revenue for Sernova while providing an important treatment option to improve the outcome and quality of life of patients suffering from chronic diseases.

    About Sertolin(TM)

    Sertolin(TM) provides an immune-protected local environment for transplanted therapeutic cells such as insulin producing islets by producing factors which modulate the local immune response. Sertolin(TM) may reduce or eliminate the need for immunosuppressant agents.

    About The Cell Pouch(TM)

    The Cell Pouch(TM) is a proprietary medical device that, following subcutaneous implantation, incorporates with tissue and microvessels forming a natural environment for transplantation of therapeutic cells. Multiple preclinical studies demonstrated that the Cell Pouch(TM) provides a safe environment for transplanted cells, and fosters the long-term efficacy of these therapeutic cells. The Cell Pouch(TM) is currently being tested in a human clinical trial in subjects with diabetes receiving an islet transplant.

    About Sernova

    Sernova Corp. is a clinical stage health-sciences company focused on commercializing medical technologies. Sernova is developing a platform technology based on the Cell Pouch(TM), Sertolin(TM) and therapeutic cells, for a number of chronic diseases, including insulin-dependent diabetes as a first indication and other cell therapies such as for parathyroid disease, haemophilia, and Parkinson's disease. Sernova's goals for the Cell Pouch(TM) for diabetes include increasing the number of patients currently treated with intraportal delivery of donor islets and to provide a safe environment for sources of unlimited insulin-secreting cells such as insulin-producing stem cells and xenogeneic cells. This vision combined with local anti- rejection protection of the cells could enable millions of patients with insulin-dependent diabetes to be treated without limitation to availability of cells.

    For further information contact:

    Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939

    Tony Russo, Ph.D. Russo Partners, LLC Tel: (212) 845-4251

    Forward Looking Information This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although Sernova believes the expectations expressed in such forward- looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of Sernova's management on the date such statements were made. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

    Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


    Press Releases from:

    2018 2017 2016 2015 2014 2013 2012

    2011 2010 2009 2008 2007 2006 2005

    2004 2003 2002 2001 2000 1999

    Featured News

    2014, January 22

    Sernova’s Disruptive Regenerative Medicine Technologies Set to Improve the Treatment of Chronic Diseases While Reducing Healthcare Costs


    2012, July 11

    Sernova Corp. developing a tiered approach to the treatment of diabetes

    Publisher: Canadian Investor Magazine
    Author: Rochelle Emnance


    2012, July 30

    Feds back local diabetes discovery

    Publisher: London Free Press
    Author: Norman De Bono

    2012, July 30

    Federal program pumps $3 million into new, London business

    Publisher: The London Free Press

    Author: Norman De Bono

    2010 July 10

    Canada's economic action plan supports business innovators

    Publisher: Federal Economic Development Agency for Southern Ontario


    2007, February 20

    "Transplanted cells may protect against diabetes without forced drug use: An interview with Dr. David White"

    Author: Julie Ickes and James Finch

    2006, October 04

    "Sertoli Cells: Mother nature's anti-rejection drug"

    Author: James Finch

    2006, August 24

    "Mass marketing diabetes reversal; novel xeno-transplants may offer new hope for type 1 diabetics"

    Author: James Finch

    Presentation and Video

    May 03, 2018

    Corporate Presentation

    April 2018

    March 29, 2018

    2018 Financial Report - 1st Quarter

    March 29, 2018

    2018 Management Discussion & Analysis (MD&A) - 1st Quarter

    December 11, 2017

    Clearance by FDA of Sernova's US IND

    Conference call audio recording

    September 11, 2017

    Sernova Fact Sheet

    Subscribe to Sernova News